Reversible Resistance of Renal Cell Carcinoma to Sorafenib
Author Information
Author(s): Zhang Liang, Bhasin Manoj, Schor-Bardach Rachel, Wang Xiaoen, Collins Michael P., Panka David, Putheti Prabhakar, Signoretti Sabina, Alsop David C., Libermann Towia, Atkins Michael B., Mier James W., Goldberg S. Nahum, Bhatt Rupal S.
Primary Institution: Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
Hypothesis
Resistance to antiangiogenic therapy in renal cell carcinoma may be reversible due to physiological changes rather than permanent genetic alterations.
Conclusion
Resistance to sorafenib in renal cell carcinoma appears to be reversible, suggesting that treatment breaks may restore sensitivity to therapy.
Supporting Evidence
- Reimplanted tumors maintained their ability to stabilize on sorafenib despite prior resistance.
- Gene expression profiles of reimplanted tumors resembled those of untreated tumors.
- Revascularization and reduced perfusion were observed upon re-exposure to sorafenib.
Takeaway
This study found that some kidney cancer cells can stop resisting a drug called sorafenib if they take a break from it, which means they can be treated again later.
Methodology
Mice with human renal cell carcinoma xenografts were treated with sorafenib, and tumor growth and gene expression were analyzed before and after treatment breaks.
Limitations
The study was conducted in mouse models, which may not fully replicate human responses.
Statistical Information
P-Value
0.0029
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website